Monsanto, now owned by Bayer, is still facing **billion-dollar lawsuits related to its Roundup herbicide** as of late 2025. Despite having settled a large number of claims, tens of thousands of cases remain active in both federal and state courts. These lawsuits primarily allege that exposure to Roundup’s active ingredient, glyphosate, caused non-Hodgkin’s lymphoma and that Monsanto/Bayer failed to adequately warn users about the cancer risks.
The scale of litigation is immense. Around **170,000 claims** have been filed alleging cancer caused by Roundup exposure. Of these, Bayer has settled roughly **100,000 claims for about $11 billion**, but there are still **over 4,400 cases pending in federal court** alone. The company has been ordered to pay **more than $6 billion in verdicts** since late 2023, with total jury awards exceeding **$8 billion** to victims so far. These figures reflect the ongoing financial and legal pressure Bayer faces from Roundup litigation.
Trials continue to be held, with some recent verdicts affirming large punitive damages against Monsanto. For example, a $175 million verdict awarded to an elderly plaintiff with non-Hodgkin’s lymphoma was upheld by a Pennsylvania appellate court in 2025, reinforcing the jury’s finding that Monsanto’s product caused the cancer and that the company failed to warn consumers properly. However, not all trials have gone against Monsanto; some juries have ruled in favor of the company when evidence was deemed insufficient.
Bayer has also been actively trying to limit the lawsuits through legal maneuvers, including appeals to the U.S. Supreme Court arguing that federal law preempts state claims because the Environmental Protection Agency (EPA) has not required a cancer warning label on glyphosate products. These attempts have so far been unsuccessful, with courts continuing to allow state-level lawsuits to proceed.
In addition to personal injury lawsuits, there have been class action suits focused on Monsanto’s labeling practices, accusing the company of deceptive marketing by claiming glyphosate only targets plant enzymes, while allegedly knowing it could affect human gut bacteria. These suits seek refunds for product purchases rather than personal injury damages.
Bayer has set aside substantial funds to cover ongoing litigation costs and settlements, recently adding an additional billion dollars to its litigation reserve. This move signals that the company is preparing for continued legal battles and potential new settlements in the near future.
For individuals diagnosed with non-Hodgkin’s
